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Key messages
What is already known about this subject?
 ► Interleukin (IL)-23-producing myeloid cells 
are thought to be key to the pathogenesis of 
closely related disease such as psoriasis and 
inflammatory bowel disease.
 ► The enthesis is considered the cardinal 
lesion in psoriatic arthritis (PsA) and 
spondyloarthropathy (SpA) but it was previously 
unknown if this tissue contained a population 
of myeloid cells capable of IL-23 production.
 ► It has been considered that intestinal or 
systemically derived IL-23 may have been 
responsible for triggering enthesitis.
What does this study add?
 ► We demonstrate that normal spinal enthesis 
soft tissue and bone has resident myeloid cells.
 ► It was possible to induce IL-23 protein which 
was almost exclusive to a population of CD14+ 
myeloid cells.
How might this impact on clinical practice or 
future developments?
 ► This study increases the understanding of innate 
immunity at the normal healthy human enthesis 
that needs further study to understand how this 
might contribute to blocking IL-23 efficacy, or 
not in some settings, in PsA and SpA.
AbSTrACT
Objective We investigated whether the normal 
human spinal enthesis contained resident myeloid 
cell populations, capable of producing pivotal 
proinflammatory cytokines including tumour necrosis 
factor (TnF) and interleukin (il)-23 and determined 
whether these could be modified by PDe4 inhibition.
Methods normal human enthesis soft tissue (sT) 
and adjacent perientheseal bone (PeB) (n=15) were 
evaluated using immunohistochemistry (iHc), digested 
for myeloid cell phenotyping, sorted and stimulated with 
different adjuvants (lipopolysaccharide and mannan). 
stimulated enthesis fractions were analysed for inducible 
production of spondyloarthropathy disease-relevant 
mediators (il-23 full protein, TnF, il-1β and ccl20). 
Myeloid populations were also compared with matched 
blood populations for further mrna analysis and the 
effect of PDe4 inhibition was assessed.
results a myeloid cell population (cD45+ 
HlaDr+ cD14+ cD11c+) phenotype was isolated from 
both the sT and adjacent PeB and termed ’cD14+ 
myeloid cells’ with tissue localisation confirmed by 
cD14+ iHc. The cD14− fraction contained a cD123+ 
HlaDr+ cD11c− cell population (plasmacytoid dendritic 
cells). The cD14+ population was the dominant 
entheseal producer of il-23, il-1β, TnF and ccl20. 
il-23 and TnF from the cD14+ population could be 
downregulated by a PDe4i and other agents (histamine 
and 8-Bromo-caMP) which elevate caMP. entheseal 
cD14+ cells had a broadly similar gene expression 
profile to the corresponding cD14+ population from 
matched blood but showed significantly lower ccr2 
gene expression.
Conclusions The human enthesis contains a cD14+ 
myeloid population that produces most of the inducible 
il-23, il-1β, TnF and ccl20. This population has similar 
gene expression profile to the matched blood cD14+ 
population.
InTrOduCTIOn
Synovitis is the primary lesion in rheumatoid 
arthritis (RA), whereas in spondyloarthropathy 
(SpA)-related diseases, enthesitis is the cardinal 
lesion.1 Psoriatic arthritis (PsA) and the associ-
ated SpA disorders are linked to multiple genetic 
polymorphisms in the interleukin (IL)-23/17 axis. 
Manipulation of this pathway results in an enthesi-
tis-dependent murine arthritis and several popula-
tions of IL-23R positive cells reside at the normal 
murine and human enthesis.1–4 The observed 
difference in efficacy of IL-23/17 axis blockers and 
phosphodiesterase 4 inhibitor (PDE4I) therapy in 
RA and SpA may be a result of immunopathogenic 
differences linked to the location of the primary site 
of inflammation.1 5 6
The prevailing theories have proposed that the 
IL-23 driving enthesitis originates at remote sites 
including the gut.3 In both human psoriasis and 
mouse models of psoriasis, the major producers of 
IL-23 are skin resident myeloid cells.7 Studies also 
implicate myeloid cells in human enthesitis with 
macrophages being present in early SpA-related 
enthesitis.8 A recent mouse model of mechanical 
strain also confirmed enthesitis was dependent on 
myeloid infiltration.9
Accordingly, we hypothesised that the human 
enthesis harbours a population of myeloid cells 
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Figure 1 Immunohistochemistry of CD14+ cells in (A) perientheseal bone (PEB) and (B) entheseal soft tissue (ST). Enthesis samples were separated 
into PEB and ST and CD14+ and CD14− cells sorted. (C–J) CD14+ and CD14− fractions were stimulated with LPS/interferon gamma (IFNү) or 
mannan for 48 hours. TNF, IL-23, CCL20 and IL-1β levels were measured by ELISA. n=5. Two-way analysis of variance (ANOVA) with Bonferroni 
multiple comparisons test was performed. *Significance from relevant unstimulated control, for example, CD14+ or CD14− unstimulated. (K) PEB was 
stimulated with LPS/IFNү in the presence of Golgi plug for 16 hours. Cells were surface stained for CD14+ and CD14− cells and intracellular IL-23p19 
were measured. Blue histograms represent unstimulated and red stimulated. (L) Change in IL-23p19 median fluorescence intensity (MFI), following 
LPS/IFNү stimulation in both CD14+ and CD14− gates. n=3. Paired t-test. *p<0.05; **p<0.01; ***p<0.001. IL, interleukin; LPS, lipopolysaccharide; 
PEB, perientheseal bone; ST, soft tissue; TNF-α, tumour necrosis factor alpha.
capable of proinflammatory cytokine production. We investi-
gated whether potential IL-23 secretion could be modulated by 
PDE4 inhibition, a target pathway known to show efficacy in 
PsA but not RA.
MATerIAlS And MeTHOdS
Comprehensive materials and methods can be found in online 
supplementary materials. Briefly, for tissue collection, normal 
spinous process enthesis was obtained from 15 patients (6 men 
and 9 women; median age 46 years) who were undergoing spinal 
decompression or surgery for scoliosis correction of thoracic 
or lumbar vertebrae using previously described methods4 (see 
online supplementary figure 1). The study protocol of the current 
investigation was approved by North West-Greater Manchester 
West Research Ethics Committee.
Statistical analysis
Statistical significance was calculated using a one or two-way anal-
ysis of variance with Bonferroni's multiple comparisons test, unless 
stated. Analysis was performed using Prism software (GraphPad 
software V.8.0, La Jolla, CA, USA). Error bars represent the SEM.
reSulTS
Myeloid cells are present in entheseal soft tissue and bone 
and can produce Il-23
Following the digestion of both the perientheseal bone (PEB) and 
soft tissue (ST) enthesis and flow cytometry analysis, a myeloid 
CD45+ CD14+ HLADR+ CD11c+ (hereafter referred to 
as the CD14+ population) and a CD45+ CD14− (hereafter 
referred to as the CD14− population) of cells were evident (see 
online supplementary figures 2–4). Within the CD14− fraction, a 
CD123+HLADR+ CD11c− (plasmacytoid dendritic cell) popu-
lation was identified, accounting for 1% of CD45+ cells (online 
supplementary figure 2). Due to demands of using multiple colours 
for flow cytometry, we decided to exclude the analysis of ILC3 cells, 
which we have previously identified at the human enthesis.4 Histo-
logical staining of both the PEB and ST showed CD14+ enthesis 
immune cell populations (figure 1A, B). For control staining and 
isotype control, see online supplementary figure 5.
Following the isolation of CD14+ and CD14− fractions by 
fluorescence-activated cell sorting (FACS), they were stimulated 
with either mannan or lipopolysaccharide (LPS) and interferon 
gamma (IFNγ). Disease-relevant cytokines and chemokines, 
tumour necrosis factor (TNF), IL-23 (full protein p40+p19), 
CCL20 and IL-1β were measured by ELISA (figure 1C–J). IL-23 
and CCL20 were only inducible from CD14+ cells (red box 
plots) following stimulation (figure 1E–H). While both frac-
tions CD14+ and CD14− showed inducible TNF and IL-1β 
following stimulation, this was only statistically significant in the 
CD14+ fraction (figure 1C, D, I, J).
In terms of weight, the PEB contained more CD14+ per gram 
than the ST (mean=7.9×104 vs 6.8×103). Because of the scarcity 
of available cells in the ST, CD14+ and CD14− cells were seeded 
at a lower density than those from the bone (see the Materials and 
methods section). The individual CD14+ myeloid cell production 
of IL-23 and TNF expressed as pg/cell was not significantly different 
between PEB and ST (online supplementary figure 6). Intracel-
lular staining for IL-23 of both CD14+ and CD14− populations 
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Figure 2 (A–D) CD14+ fraction cells were isolated from the PEB and ST as before (n=5), and stimulated with LPS/IFNү and mannan as before, with 
and without PDE4I rolipram, IL-23 and TNF were measured by ELISA. (E, F) Healthy blood CD14+ cells were stimulated with LPS/IFNү (E) or mannan 
(F) with and without cAMP-elevating agents; rolipram, 8-Br-cAMP and histamine for 48 hours (n=7), IL-23 secretion was measured by ELISA. One-
way analysis of variance (ANOVA) with Bonferroni multiple comparisons test was performed. (E, F) Significance from stimulated (LPS or mannan). (G) 
CD14+ cells were isolated from the PEB or matched blood and transcript analysis was performed (n=4). Black bars represent those higher expressed 
in blood, white bars those with higher expression in PEB. Genes highlighted in blue were undetectable in both blood and PEB. A paired t-test was 
performed on ΔCt values for PEB versus blood. *p<0.05; **p<0.01; ***p<0.001. IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; PEB, 
perientheseal bone; ST, soft tissue; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.
following LPS/IFNγ stimulation also confirmed CD14+ as the 
exclusive IL-23 producer in the PEB (figure 1K, L).
Pde4I and other cAMP-elevating agents inhibit Il-23 from 
Cd14+ entheseal and blood myeloid cells
From figure 1, it was evident that CD14+ cells were the exclu-
sive IL-23 producers. We next tested the ability of a PDE4I 
(rolipram) to modulate IL-23 secretion. Rolipram is widely used 
in vitro to study the effects of PDE4 inhibition and has a similar 
profile to apremilast.10 Blockade of the PDE4 pathway is effi-
cacious in PsA but not RA. Rolipram effectively inhibited both 
mannan/IFNγ and LPS/IFNγ-induced IL-23 and TNF from the 
CD14+ fraction from both ST and PEB (figure 2A–D).
PDE4Is are thought to modulate inflammatory pathways via 
elevating cAMP. Due to the low number of cells yielded from the 
enthesis, cAMP pathway exploratory research on IL-23 secretion 
was conducted on the corresponding CD14+ population in blood 
from healthy donors. CD14+ cells were isolated by FACS and 
stimulated with LPS/IFNγ (figure 2E) or mannan/IFNγ (figure 2F) 
as before. To access the importance of the cAMP pathway in 
PDE4I attenuation of IL-23 production, other molecules known to 
activate the cAMP pathway (histamine and 8-Bromo-cAMP) were 
tested for their ability to inhibit IL-23 secretion and confirm the 
importance of the PDE4 pathway on these cells (figure 2E, F).
entheseal myeloid cells share a similar gene profile to 
matched blood cells
In order to provide further functional characterisation of 
CD14+ myeloid cells in the enthesis, entheseal cells were 
compared with those isolated from matched blood (figure 2G). 
Both populations had a broadly similar gene expression profile. 
The majority of genes analysed did not have a greater than 
twofold difference and only CCR2 expression was statistically 
significant (figure 2G). However, the majority of inflammatory 
cytokines and inflammatory signalling pathways trended higher 
in the blood population.
dISCuSSIOn
In this study, we report that both normal entheseal ST and 
adjacent bone have a population of CD45+ CD14+ HLDR+ 
CD11c+ myeloid cells. Entheseal CD14+ cells are capable of 
producing IL-23, TNF, IL-1β and CCL20. Moreover, IL-23 and 
TNF induction can be reduced by PDE4 inhibition. These obser-
vations may also be of relevance to disease, given that both PDE4 
inhibitors and IL-23 blockers show efficacy in PsA but not RA.
In a landmark IL-23-dependent enthesitis mouse model of SpA, 
it was shown that in vivo hepatic expression of IL-23 induced 
enthesitis via an effect on resident enthesis T cells and it was 
considered that the IL-23 effect was via systemically released cyto-
kine.3 Presently, there are no reports of normal enthesis myeloid 
cells with the ability to secrete IL-23 locally. Herein we show that 
cells capable of producing IL-23 are present at the enthesis and that 
virtually all of the IL-23 was from the CD14+ fraction as opposed 
to the CD14− fraction. This highlights the potential importance 
of this myeloid cell population in disease initiation. Both bacterial 
and fungal adjuvants were able to induce IL-23 production from 
the CD14+ fraction. In agreement with this, in the SKG mouse 
model of arthritis where pathology originates as enthesitis, both 
curdlan and chlamydia promote disease.11 12 Moreover, previous 
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research has shown myeloid cells such as macrophages in the early 
inflamed SpA enthesis.8
It was previously unknown if IL-23-producing myeloid cells 
at the enthesis were resident or tissue infiltrating. Classification 
of myeloid cell subsets within tissues is notoriously difficult and 
remains controversial. A new single-cell RNA-seq approach may 
be the only way to truly define the myeloid subsets.13 During 
inflammation, classical monocytes (defined as CD14high 
CD16low) enter tissues in a CCR2-CCL2 dependent manner. 
In a recent mouse model of biomechanical loading, arthritis 
was dependent on CCL2 production and subsequent monocyte 
recruitment.9 The myeloid cells we described at the enthesis may 
be non-classical monocytes. It is known that non-classical mono-
cytes migrate and ‘patrol’ peripheral tissues, so are not defined 
as tissue resident macrophages in the sense of microglial or 
Kupffer cells.14 Non-classical monocytes (defined as CD14low 
CD16high) are known to express less CCR2 and inflammatory 
mediators when compared with classical monocytes, which 
would align with our findings.14 Entheseal myeloid cells in our 
study indeed showed statistically significantly less expression of 
CCR2, while basal production of inflammatory mediators such 
as IL-1β, IL-6 and TNF trended downwards.
We also report that fungal and bacterial adjuvants are able to 
induce CCL20 from enthesis CD14+ cells, but not CD14– cells. 
CCL20 is a chemokine that attracts IL-17-expressing cells via its 
ligand CCR6. In agreement with this, PsA synovial fluid levels of 
CCL20 correlate with disease severity.15 IL-17-expressing ILC3 
and T cells are also CCR6+ from the synovial fluid of patients 
with PsA.16 17 These findings suggest a link between enthesis 
myeloid cells and the cells that preferentially accumulate in the 
adjacent joint cavity in PsA.
While therapeutic blockage of IL-23 has demonstrated effi-
cacy in PsA, recent results from a clinical trial in patients with 
ankylosing spondylitis have proved disappointing.18 It has been 
hypothesised that variation in efficacy may be due to a differing 
immunopathogenesis including different immune cell popula-
tions between the spine and peripheral joint.19 A recent paper 
using an HLA-B27 rat model showed that SpA pathology is 
dependent on IL-23 for initiation but not disease persistence.20 
This may indeed point towards the idea of IL-17 independent of 
IL-23 for disease progression, while IL-23 is required for disease 
initiation. Related research has shown that torn supraspinatus 
tendon contains IL-17+ cells including T cells; however, it is not 
known if these cells can produce IL-17 independently of IL-23.21
PDE4Is are thought to mediate anti-inflammatory effects by 
elevating cAMP. Other cAMP pathway activators such as hista-
mine and 8-Bromo-cAMP are known to attenuate inflammatory 
cytokine production from peripheral blood mononuclear cells; 
however, this is the first report showing this on tissue myeloid 
cells.22 Previous research has suggested cAMP-elevating agents 
downregulate IL-12p40, the common chain between IL-12 and 
IL-23, which in theory may also account for the downregulation 
of full IL-23 protein (p19+p40) observed (figure 2A–D).22 Further 
work is required to decipher the exact mechanisms in which cAMP 
elevation regulates individual IL-12 family member chains.
In conclusion, these data demonstrate that the normal enthesis 
contains a population of myeloid cells capable of local innate 
cytokine production including TNF and IL-23. While CD14+ 
HLADR+ CD11c+ confirm the presence of a myeloid pheno-
type, further work is required to fully characterise this popu-
lation. The in vivo triggers of myeloid-derived TNF and IL-23 
remain to be fully elucidated but our findings show that the 
normal enthesis contains myeloid cells capable of locally contrib-
uting to disease.
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